CAN effectively downregulated tTLR-4 (p < 0.001), NF-κB p65 (p < 0.001), and iNOS (p < 0.01) in the lungs of CIS-treated rats while had no effect in normal rats. The gene discussed is NFKB1; the disease is in situ carcinoma.